Oxurion Extends Financing Program with Atlas Special Opportunities

Biopharmaceutical company Oxurion NV, based in Leuven, Belgium, has signed a fourth amendment to its financing agreement with Atlas Special Opportunities II, LLC. The amendment prolongs the overall program by 12 months, now extending until March 2, 2027. Additionally, it aligns the maturity terms of all bonds, both issued and yet to be issued, to 72 months from their issue date. This amendment facilitates a consistent bond maturity structure.

To qualify for bond issuance, Oxurion must maintain a minimum market capitalization of EUR 500,000 over a 30-day period. Should it temporarily dip to EUR 250,000, a partial drawdown of EUR 150,000 is permissible under specific conditions. The amendment requires a total trading volume of EUR 1.2 million over 22 days, reduced to EUR 600,000 for partial drawdowns. The option to transfer bonds to affiliated entities outside the U.S. is also granted without company consent.